Novo Nordisk A/S (NVO) Discusses Extraordinary General Meeting on Proposed Board Changes and Governance Transcript
Novo Nordisk A/S (NVO) Discusses Extraordinary General Meeting on Proposed Board Changes and Governance October 21, 2025 9:00 AM EDT Company Participants Jacob Martin Rode - Head of Investor Relations Lars Rebien Sørensen Conference Call Participants Richard Vosser - JPMorgan Chase & Co, Research Division Peter Verdult - BNP Paribas Exane, Research Division Conor MacKay - BMO Capital Markets Equity Research Michael Leuchten Carsten Madsen - Danske Bank A/S, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Emmanuel Papadakis - Deutsche Bank AG, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Presentation Operator Good day, and thank you for standing by.
Novo Nordisk to Replace Chairman and Other Board Members
An extraordinary meeting will take place next month to vote on new members after the company and its controlling shareholder failed to agree on the board's composition.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Oct 2025)
Ozempic has become a phenomenon, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk
The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events.
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound.
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
Novo Nordisk (NVO) concluded the recent trading session at $56.09, signifying a -1.11% move from its prior day's close.
Novo Nordisk's Akero Therapeutics Buy Targets Eli Lilly's Lead
Novo Nordisk A/S NYSE: NVO recently announced plans to acquire Akero Therapeutics. The deal, which is valued at around $4.7 billion, is scheduled to close early in 2026.
Focus: Inside Novo Nordisk's 'Club 5,000' as Danish staff cuts gain pace
Romel Amineh is one of a fast-growing group of Novo Nordisk workers in Denmark laid off as the drugmaker battles to cut costs and revive its fortunes in a fiercely competitive global obesity drug market. They call themselves the "Club 5,000".
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Novo Nordisk A/S (NVO) M&A Call Transcript
Novo Nordisk A/S (NVO) M&A Call October 9, 2025 8:00 AM EDT Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Management Board Ludovic Helfgott - Executive VP of Product & Portfolio Strategy and Member of Management Board Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Harry Sephton - UBS Investment Bank, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Peter Verdult - BNP Paribas Exane, Research Division Conor MacKay - BMO Capital Markets Equity Research Michael Nedelcovych - TD Cowen, Research Division Michael Leuchten - Jefferies LLC, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Thibault Boutherin - Morgan Stanley, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
2 Beaten-Down Stocks Primed for a Comeback
Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present.
